vs

Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

Chatham Lodging Trust is the larger business by last-quarter revenue ($67.5M vs $36.2M, roughly 1.9× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -1.6%). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs -11.6%).

Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

CLDT vs INFU — Head-to-Head

Bigger by revenue
CLDT
CLDT
1.9× larger
CLDT
$67.5M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+8.7% gap
INFU
7.0%
-1.6%
CLDT
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
-11.6%
CLDT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLDT
CLDT
INFU
INFU
Revenue
$67.5M
$36.2M
Net Profit
$725.0K
Gross Margin
56.4%
Operating Margin
2.4%
10.3%
Net Margin
1.1%
Revenue YoY
-1.6%
7.0%
Net Profit YoY
EPS (diluted)
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLDT
CLDT
INFU
INFU
Q1 26
$67.5M
Q4 25
$67.7M
$36.2M
Q3 25
$78.4M
$36.5M
Q2 25
$80.3M
$36.0M
Q1 25
$68.6M
$34.7M
Q4 24
$75.1M
$33.8M
Q3 24
$87.2M
$35.3M
Q2 24
$86.5M
$33.7M
Net Profit
CLDT
CLDT
INFU
INFU
Q1 26
$725.0K
Q4 25
$4.6M
Q3 25
$3.5M
$2.3M
Q2 25
$5.4M
$2.6M
Q1 25
$1.5M
$-267.0K
Q4 24
$-1.7M
Q3 24
$4.3M
$1.8M
Q2 24
$6.8M
$717.0K
Gross Margin
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
56.4%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
40.7%
53.8%
Q3 24
44.7%
53.9%
Q2 24
46.1%
49.5%
Operating Margin
CLDT
CLDT
INFU
INFU
Q1 26
2.4%
Q4 25
15.9%
10.3%
Q3 25
12.7%
10.4%
Q2 25
14.8%
10.5%
Q1 25
12.1%
1.8%
Q4 24
7.5%
7.7%
Q3 24
14.3%
9.2%
Q2 24
16.3%
5.5%
Net Margin
CLDT
CLDT
INFU
INFU
Q1 26
1.1%
Q4 25
6.8%
Q3 25
4.5%
6.2%
Q2 25
6.7%
7.2%
Q1 25
2.2%
-0.8%
Q4 24
-2.3%
Q3 24
4.9%
5.1%
Q2 24
7.9%
2.1%
EPS (diluted)
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
$0.05
$0.09
Q3 25
$0.03
$0.11
Q2 25
$0.07
$0.12
Q1 25
$-0.01
$-0.01
Q4 24
$-0.08
$0.05
Q3 24
$0.05
$0.08
Q2 24
$0.10
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLDT
CLDT
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$13.7M
$3.2M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$722.9M
$57.3M
Total Assets
$1.2B
$100.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLDT
CLDT
INFU
INFU
Q1 26
$13.7M
Q4 25
$24.4M
$3.2M
Q3 25
$13.2M
$955.0K
Q2 25
$17.2M
$720.0K
Q1 25
$18.6M
$1.5M
Q4 24
$20.2M
$527.0K
Q3 24
$19.3M
$380.0K
Q2 24
$10.6M
$146.0K
Total Debt
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
$338.9M
$19.6M
Q3 25
$338.8M
$20.9M
Q2 25
$351.2M
$26.3M
Q1 25
$381.1M
$28.7M
Q4 24
$406.9M
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Stockholders' Equity
CLDT
CLDT
INFU
INFU
Q1 26
$722.9M
Q4 25
$740.8M
$57.3M
Q3 25
$749.4M
$55.5M
Q2 25
$754.1M
$54.5M
Q1 25
$754.7M
$55.1M
Q4 24
$758.2M
$57.5M
Q3 24
$765.3M
$55.5M
Q2 24
$766.5M
$53.5M
Total Assets
CLDT
CLDT
INFU
INFU
Q1 26
$1.2B
Q4 25
$1.2B
$100.6M
Q3 25
$1.2B
$98.9M
Q2 25
$1.2B
$100.8M
Q1 25
$1.2B
$104.3M
Q4 24
$1.3B
$103.6M
Q3 24
$1.3B
$105.3M
Q2 24
$1.3B
$108.5M
Debt / Equity
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
0.46×
0.34×
Q3 25
0.45×
0.38×
Q2 25
0.47×
0.48×
Q1 25
0.50×
0.52×
Q4 24
0.54×
0.41×
Q3 24
0.50×
Q2 24
0.64×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLDT
CLDT
INFU
INFU
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
$64.1M
$7.1M
Q3 25
$25.6M
$8.5M
Q2 25
$22.1M
$7.0M
Q1 25
$4.2M
$1.8M
Q4 24
$73.8M
$7.9M
Q3 24
$28.8M
$9.8M
Q2 24
$25.2M
$2.3M
Free Cash Flow
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$1.6M
Q4 24
$7.4M
Q3 24
$9.8M
Q2 24
$2.0M
FCF Margin
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
19.3%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
4.7%
Q4 24
21.9%
Q3 24
27.7%
Q2 24
5.9%
Capex Intensity
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
0.4%
Q4 24
1.6%
Q3 24
0.1%
Q2 24
1.0%
Cash Conversion
CLDT
CLDT
INFU
INFU
Q1 26
Q4 25
13.90×
Q3 25
7.24×
3.76×
Q2 25
4.10×
2.70×
Q1 25
2.73×
Q4 24
Q3 24
6.78×
5.45×
Q2 24
3.68×
3.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLDT
CLDT

Room$61.2M91%
Other$4.7M7%
Food and beverage$1.6M2%

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons